Prediction of the emergence of HBV mutant by the antiviral treatment by using next-generation sequencer

Prediction of the emergence of HBV mutant by the antiviral treatment by using next-generation sequencer - Analysis of the HBV mutant by using next-generating sequencer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018701

Enrollment

300

Registered

2015-08-21

Start date

2015-08-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis B (1) Patients who obtained the document, the consent to participate in research in the description (2)Patients who do not belong to the exclusion criteria

Exclusion criteria

Exclusion criteria: (1) the patients who are not detect HBVDNA in peripheral blood (2) the patients who cannot consult our department periodically (3) the patients who are not appropriate to entry for this examination by doctors

Design outcomes

Primary

Measure	Time frame
Comparison of the rate of the wild and mutant strain before medical treatment, and the rate of each stock under medical treatment	—

Countries

Japan

Contacts

Public ContactYoshiki Murakami

Graduate School of Medicine, Osaka City University Department of Hepatology

m2979633@med.osaka-cu.au.jp81-6-6645-3811

Outcome results